Oaktree Fund Advisors’s Mesoblast MESO Stock Holding History

Oaktree Fund Advisors’s Portfolio MESO Stock Details MESO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-47,909	Closed	-$949K	–	53
2024 Q4	$949K	Buy	+47,909	New	+$531K	1.59%	18

Other funds holding MESO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

SXL

Summit X LLC Chesterfield, Missouri $536M AUM 15.36% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Marex Group London $15.8B AUM 31.44% 1-Year Est. Return

Oaktree Fund Advisors's MESO Position: Q1 2025 in Review

Oaktree Fund Advisors sold out of Mesoblast (MESO) in Q1 2025, closing a stake of 47,909 shares — an estimated $949K sold.

Oaktree Fund Advisors first reported a position in MESO in Q4 2024 and held it in 1 quarter. The position peaked at $949K in Q4 2024. 68 funds tracked by Wall St. Rank hold MESO as of Q1 2025.

Oaktree Fund Advisors reported no remaining Mesoblast position as of Q1 2025 after selling out during the quarter.
Oaktree Fund Advisors sold 47,909 Mesoblast shares in Q1 2025, an estimated $949K.
Oaktree Fund Advisors first reported a position in Mesoblast in Q4 2024 and held it in 1 quarter.
Oaktree Fund Advisors's Mesoblast position peaked at $949K in Q4 2024.
68 funds tracked by Wall St. Rank held Mesoblast as of Q1 2025.

Based on Oaktree Fund Advisors's 13F filing for Q1 2025, filed 15 May 2025.